Evidence map›Paper›PMID 39786454›Full record

ReviewCurrent cardiology reports2025

Desmoplakin Cardiomyopathy: Role of Inflammation and Potential Role of Disease-Modifying Therapies.

Alessio Gasperetti, Richard T Carrick, Steven Muller, Brittney Murray, Luigi Adamo, Barbara Bauce, Elizabeth McNally, Adam Helms

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alessio GasperettiDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. alessio.gasperetti93@gmail.com.
Richard T CarrickDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Steven MullerDepartment of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Brittney MurrayDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Luigi AdamoDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Barbara BauceDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
Elizabeth McNallyCenter for Genetic Medicine and Bluhm Cardiovascular Institute, Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Adam HelmsDepartment of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo summarize the available data on the use of immunosuppression therapies for the management of hot phases of disease and recurrent myocarditis in patients with desmoplakin cardiomyopathy (DSP-CMP). RECENT

findingsOccurrence of myocarditis episodes has been associated with worsening of outcomes in DSP-CMP. Multiple case reports and small case series have described potential benefit in using anti-inflammatory and immunosuppressive medications for the treatment of those episodes. Recently published translational data has shown a clear link between DSP variants and a propensity to inflammation. The presence of acute myocarditis episodes have been clearly demonstrated as a manifestation of DSP-CMP. These episodes are marked by myocardial inflammation and subsequent fibrosis, and, moreover, contribute to a heightened future risk of subsequent arrhythmias and heart failure. Identifying optimal strategies to prevent and/or interrupt myocardial inflammation is therefore a critical priority of patients with DSP-CMP.

Indexed as

CardiomyopathiesDesmoplakinsMyocarditisAnti-Inflammatory AgentsHumansImmunosuppressive AgentsInflammationAnti-Inflammatory AgentsDesmoplakinsImmunosuppressive AgentsArrhythmogenic cardiomyopathyDSPDSP-cardiomyopathyImmunosuppressionMyocarditis

Identifiers

PMID39786454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.